In this issue:
Recent childbirth a risk factor for breast cancer
Adding palbociclib to letrozole in the neoadjuvant setting
Risk for cognitive decline among older breast cancer survivors
Endocrine activity of neoadjuvant degarelix or triptorelin + letrozole
Patient-reported outcomes after hypofractionated breast RT
Dasatinib sensitises TNBC cells to chemotherapy
Extending letrozole therapy after 5 years of endocrine therapy
Comparing chemotherapy backbones combined with dual HER2 blockade
Considering dose tailoring in obese patients
9 weeks vs 1 year of adjuvant trastuzumab
Please login below to download this issue (PDF)